Evidence map›Paper›PMID 24926563›Full record

ArticleOncology reports2014

Combined effects of asbestos and cigarette smoke on the development of lung adenocarcinoma: different carcinogens may cause different genomic changes.

Kentaro Inamura, Hironori Ninomiya, Kimie Nomura, Eiju Tsuchiya, Yukitoshi Satoh, Sakae Okumura, Ken Nakagawa, Ayako Takata, Norihiko Kohyama, Yuichi Ishikawa

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Kentaro InamuraDivision of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Koto-ku, Tokyo 135‑8550, Japan.
Hironori NinomiyaDivision of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Koto-ku, Tokyo 135‑8550, Japan.
Kimie NomuraDivision of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Koto-ku, Tokyo 135‑8550, Japan.
Eiju TsuchiyaDivision of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Koto-ku, Tokyo 135‑8550, Japan.
Yukitoshi SatohDepartment of Thoracic Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 228‑8555, Japan.
Sakae OkumuraDepartment of Thoracic Surgery, The Cancer Institute Hospital, JFCR, Koto-ku, Tokyo 135‑8550, Japan.
Ken NakagawaDepartment of Thoracic Surgery, The Cancer Institute Hospital, JFCR, Koto-ku, Tokyo 135‑8550, Japan.
Ayako TakataDepartment of Preventive Medicine, St. Marianna University School of Medicine, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan.
Norihiko KohyamaFaculty of Economics, Toyo University, Bunkyo-ku, Tokyo 12-8608, Japan.
Yuichi IshikawaDivision of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Koto-ku, Tokyo 135‑8550, Japan.
Japanese Foundation For Cancer Research · JPThe Cancer Institute Hospital · JPKitasato University · JPSt. Marianna University School of Medicine · JPToyo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The carcinogens in cigarette smoke are distinct from asbestos. However, an understanding of their differential effects on lung adenocarcinoma development remains elusive. We investigated loss of heterozygosity (LOH) and the p53 mutation in 132 lung adenocarcinomas, for which asbestos body burden (AB; in numbers per gram of dry lung) was measured using adjacent normal lung. All cases were classified into 9 groups based on a matrix of cumulative smoking (CS in pack‑years; CS=0, 0<CS<25, ≥25 CS) and AB (AB=0, 0<AB<1,000, ≥1,000 AB). AB=0 indicates a lower level than the detection limit of ~100. LOH frequency increased only slightly with the elevation of CS in the AB=0 groups. In the AB>0 groups, LOH frequency increased as AB and/or CS was elevated and was significantly higher in the ≥1,000 AB, ≥25 CS group (p=0.032). p53 mutation frequency was the lowest in the AB=0, CS=0 group, increased as AB and/or CS rose, and was significantly higher in the ≥1,000 AB, ≥25 CS group (p=0.039). p53 mutations characteristic of smoking were frequently observed in the CS>0 groups contrary to non-specific mutations in the CS=0, AB>0 groups. Combined effects of asbestos and smoking were suggested by LOH and p53 analyses. Sole exposure to asbestos did not increase LOH frequency but increased non‑specific p53 mutations. These findings indicate that the major carcinogenic mechanism of asbestos may be tumor promotion, acting in an additive or synergistic manner, contributing to the genotoxic effect of smoking. Since this study was based on a general cancer center's experience, the limited sample size did not permit the consideration that the result was conclusive. Further investigation with a large sample size is needed to establish the mechanism of asbestos-induced lung carcinogenesis.

Indexed as

Loss of HeterozygosityAdenocarcinomaAdenocarcinoma of LungAdultAgedAsbestosCocarcinogenesisFemaleHumansLung NeoplasmsMaleMiddle AgedOccupational ExposureSmokingTumor Suppressor Protein p53AsbestosTumor Suppressor Protein p53

Identifiers

PMID24926563
PMCPMC4091886
OpenAlexW2120333186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.